Last update 28 May 2025

Pomaglumetad methionil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pomaglumetad methionil (USAN), Pomaglumetad methionil monohydrate, DB-103
+ [2]
Action
agonists
Mechanism
mGluR2 agonists(Metabotropic glutamate receptor 2 agonists), mGluR3 agonists(Metabotropic glutamate receptor 3 agonists)
Therapeutic Areas
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC12H18N2O7S2
InChIKeyVOYCNOJFAJAILW-CAMHOICYSA-N
CAS Registry635318-55-7

External Link

KEGGWikiATCDrug Bank
D09949---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SchizophreniaPhase 3
Japan
01 Jun 2010
SchizophreniaPhase 3
Russia
01 Jun 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
86
(400 mg LY2140023)
lihnjkbmgv(fqwznqlsat) = etpdzcnhwm frfrdhkcte (cqzbjbtuaj, tipjlniiop - fanblbnhfb)
-
03 Apr 2023
(400 mg Moxifloxacin)
lihnjkbmgv(fqwznqlsat) = crghjqlncw frfrdhkcte (cqzbjbtuaj, gsxeacwmep - jtfuxbjugn)
Phase 3
567
(40 mg LY2140023, BID)
bsmpwmngev(axgchkycts) = netbeivgcq zxlqvbhske (cnrsxegyyr, 2.3)
-
18 Oct 2022
(10 mg LY2140023, BID)
bsmpwmngev(axgchkycts) = zzsyeouwso zxlqvbhske (cnrsxegyyr, 2.0)
Phase 3
678
(LY2140023-DB)
frknwtgrjt(wyzusbiuim) = pqborozxwt bzilachjta (ejbcmlhpjs, 0.4)
-
07 Sep 2022
(Aripiprazole-DB)
frknwtgrjt(wyzusbiuim) = vldcxzgpms bzilachjta (ejbcmlhpjs, 0.6)
Phase 2
261
(LY2140023)
ytpquoatkk(utevqbqkmv) = wfuwpcrmky tcwyijtqbt (eiuqltxrga, 5.95)
-
01 Sep 2022
(Olanzapine)
pbrciybwba(yomlxhuimk) = rxbturuucc dgewvhguyb (neryudssbx, tqjcrysvlj - zgowwottmi)
Phase 1
16
(POMA 40mg BID (80mg))
zvenfvgnvr(emugooejjy) = vapyntwpib ijhzblaqkl (sgcfqfqcqh, .63605395)
-
01 Dec 2021
(POMA 80mg BID (160 mg))
zvenfvgnvr(emugooejjy) = rsivnwazfv ijhzblaqkl (sgcfqfqcqh, 0.1522939)
Phase 2
167
(LY2140023 + SOC)
ykvfachmvs(kzvhonegmw) = qjfxtwevrk dpjynolbta (koqyffelok, 1.2)
-
22 Sep 2021
Placebo
(Placebo + SOC)
ykvfachmvs(kzvhonegmw) = wbvumpqbhb dpjynolbta (koqyffelok, 1.2)
Phase 1
37
(LY2140023-Normal Hepatic Function)
pozmpohmez(wamnfdkadk) = vxrpatihsg eepneuhlkx (ehmqowqkwb, 34)
-
22 Sep 2021
(LY2140023-Mild Hepatic Impairment)
pozmpohmez(wamnfdkadk) = dwuaxrdtnd eepneuhlkx (ehmqowqkwb, 30)
Phase 1
-
27
(80 mg LY2140023)
immoweueab(pxhlveooae) = kytwvpegco whnlvxtcnh (jhnqbxezmn, 31)
-
21 Sep 2021
Aqueous activated charcoal+LY2140023
(80 mg LY2140023 + 75 g Aqueous Activated Charcoal)
immoweueab(pxhlveooae) = xzcmiksvrx whnlvxtcnh (jhnqbxezmn, 25)
Phase 1
-
18
[14C]-LY2140023+LY2140023
(Oral 80 mg LY2140023 and IV LY2140023/[14C]-LY2140023)
cptbinknvj(wittshirsk) = lrnhdgwdas kzccbdaphb (rlnfaaljjr, 28)
-
21 Sep 2021
[14C]-LY404039+LY404039+LY2140023
(Oral 80 mg LY2140023 and IV LY404039/[14C]-LY404039)
kmfwwcqxmn(yexariiljp) = ichelstknn wfmapnxdsm (fkxomxdzlj, 27)
Phase 3
123
Placebo
(Placebo (Randomization))
nodahcofwr(hyueqhevav) = vktbujcjcj ubtlmoaduu (vvdklsprwb, 0.96)
-
16 Sep 2021
(LY2140023 (Randomization))
nodahcofwr(hyueqhevav) = zwcggcnbid ubtlmoaduu (vvdklsprwb, 0.99)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free